Recruiting

PPOS-PCOS-IVFComparison of IVF Outcomes: PPOS vs Antagonist Protocols in Polycystic Ovary Syndrome

Study Aim

This study compares the success of two IVF treatment protocols, PPOS and Antagonist, in women with Polycystic Ovary Syndrome, by measuring the ongoing pregnancy rate at 12 weeks.

What is being tested

Progestin-Primed Ovarian Stimulation (PPOS)

+ GnRH Antagonist Protocol

Drug

Who is being recruted

Urogenital Diseases+12

+ Genital Diseases

+ Adnexal Diseases

From 18 to 40 Years

+4 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Interventional

Study Start: January 2026

See protocol details

Summary

Principal SponsorHanoi General Hospital (Vietnam)

Study ContactPhuong Duy Nguyen, MD, MS

Last updated: February 12, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: January 20, 2026

Actual date on which the first participant was enrolled.

This study focuses on comparing two different methods used in in vitro fertilization (IVF) for women with Polycystic Ovary Syndrome (PCOS), a common condition that can affect fertility. The two methods, known as the progestin-primed ovarian stimulation (PPOS) protocol and the GnRH antagonist protocol, are used to stimulate the ovaries to produce eggs. The goal is to understand which of these two approaches leads to better results for women with PCOS. This research is important as it could help improve IVF treatments and increase the chances of successful pregnancies for women with this condition. During the study, participants receive one of the two ovarian stimulation treatments. The success of each treatment is measured by the ongoing pregnancy rate at 12 weeks. This means checking for a healthy pregnancy with a heartbeat confirmed by ultrasound at or beyond 12 weeks of pregnancy. The study's primary outcome helps to determine which of the two methods results in a higher rate of ongoing pregnancies.

Official TitleA Comparative Study of In Vitro Fertilization Outcomes Between PPOS and Antagonist Protocols in Women With Polycystic Ovary Syndrome

NCT07394530

Principal SponsorHanoi General Hospital (Vietnam)

Study ContactPhuong Duy Nguyen, MD, MS

Last updated: February 12, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

400 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Female

Biological sex of participants that are eligible to enroll.

From 18 to 40 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesAdnexal DiseasesCystsEndocrine System DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleGonadal DisordersInfertilityInfertility, FemaleNeoplasmsOvarian CystsOvarian DiseasesPolycystic Ovary SyndromeFemale Urogenital Diseases

Criteria

2 inclusion criteria required to participate

Diagnosed with polycystic ovary syndrome (PCOS) according to the modified Rotterdam criteria (2004) ( >= 2 of 3: oligo/anovulation, hyperandrogenism, or polycystic ovarian morphology on ultrasound)

Willing and able to provide written informed consent and comply with study procedures

2 exclusion criteria prevent from participating

Uterine abnormalities that may impair implantation or pregnancy outcomes, including congenital uterine malformations, large fibroids distorting the uterine cavity, adenomyosis, or severe intrauterine pathology

History of recurrent pregnancy loss ( >= 3 spontaneous miscarriages)

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group

Treatment Groups

Group I

Experimental

Participants in this group undergo ovarian stimulation using the Progestin-Primed Ovarian Stimulation (PPOS) protocol for in vitro fertilization treatment.

Group II

Active Comparator

Participants in this group undergo ovarian stimulation using a GnRH Antagonist Protocol for in vitro fertilization.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Hanoi General Hospital

Hanoi, VietnamOpen Hanoi General Hospital in Google Maps

Recruiting

One Study Center